【 摘 要 】
A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was treated with surgery and oral imatinib mesylate and achieved a complete response. He is still under oral imatinib mesylate therapy. To the best of our knowledge, this is the first case of a LMSsubsequently developing GIST and DT in the intestine. As imatinib mesylate targets both c- KIT and PDGFR and since LMS, GIST and DT share the expression of c- KIT and/or PDGFR, our patient has benefited from the continual treatment with imatinib mesylate. Furthermore, tyrosine kinase inhibitors may be a possible future treatment option for LMS associated with GIST and DT.
【 授权许可】
CC BY|CC BY-ND|CC BY-NC|CC BY-NC-ND
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202107100003122ZK.pdf | 431KB | download |